Trial to evaluate the immunogenicity and safety of a melanoma helper peptide vaccine plus incomplete Freund’s adjuvant, cyclophosphamide, and polyICLC (Mel63)

BACKGROUND: Peptide vaccines designed to stimulate melanoma-reactive CD4(+) T cells can induce T cell and antibody (Ab) responses, associated with enhanced overall survival. We hypothesized that adding toll-like receptor 3 agonist polyICLC to an incomplete Freund’s adjuvant (IFA) would be safe and w...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Immunother Cancer
Main Authors: Slingluff, Jr., Craig L, Petroni, Gina R, Chianese-Bullock, Kimberly A, Wages, Nolan A, Olson, Walter C, Smith, Kelly T, Haden, Kathleen, Dengel, Lynn T, Dickinson, Anna, Reed, Caroline, Gaughan, Elizabeth M, Grosh, William W, Kaur, Varinder, Varhegyi, Nikole, Smolkin, Mark, Galeassi, Nadejda V, Deacon, Donna, Hall, Emily H
Formato: Artigo
Idioma:Inglês
Publicado em: BMJ Publishing Group 2021
Assuntos:
Clinical/Translational Cancer Immunotherapy
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7825263/
https://ncbi.nlm.nih.gov/pubmed/33479025
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/jitc-2020-000934
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados